SLC5A2 and chronic kidney disease: To examine the ostensibly renoprotective effects of SGLT2 inhibition, we used the subtotally nephrectomized rat, a model of chronic kidney disease, relevant to both diabetic and non-diabetic settings [34] and which develops a decline in GFR, the sine qua non of chronic kidney disease.